ArticleJournal of experimental & clinical cancer research : CR2012
Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells.
Article in Journal of experimental & clinical cancer research : CR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relationship of Oct-4 to malignant stage: a meta-analysis based on 502 positive/high Oct-4 cases and 522 negative/low case-free controls.Oncotarget · 2016Pooled it
- Potentially Functional Polymorphisms in POU5F1 Gene Are Associated with the Risk of Lung Cancer in Han Chinese.BioMed research international · 2015Trial
- Expression of Oct3/4 isoforms and its association with the risk of relapse in acute lymphoblastic leukemia.Biomedical reports · 2025Article
- The evaluation of cyclin D1 expression in prostate carcinoma cases.Northern clinics of Istanbul · 2024Article
- The overexpression of cyclin D1 is a positive prognostic factor in advanced-stage breast carcinoma cases.Northern clinics of Istanbul · 2023Article
- OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway.Frontiers in oncology · 2022Article
- siRNA-mediated stathmin1 silencing inhibits proliferation of prostate carcinoma cell line.Turkish journal of biology = Turk biyoloji dergisi · 2022Article
- USF1 Transcriptionally Regulates UGT1A3 and Promotes Lung Adenocarcinoma Progression by Regulating Neurotrophin Signaling Pathway.Frontiers in molecular biosciences · 2022Article
- Pluripotency Stemness and Cancer: More Questions than Answers.Advances in experimental medicine and biology · 2022Article
- FUS-dependent loading of SUV39H1 to OCT4 pseudogene-lncRNA programs a silencing complex with OCT4 promoter specificity.Communications biology · 2020Article
- Crocin enhances the viability of random pattern skin flaps: involvement of enhancing angiogenesis and inhibiting oxidative stress.American journal of translational research · 2020Article
- Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival.Journal of the Egyptian National Cancer Institute · 2019Article
- Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells.Cancer management and research · 2019Article
- OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.Oncogene · 2017Article
- Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2016Article
- Pluripotency transcription factors in lung cancer-a review.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Acquisition of tumorigenic potential and enhancement of angiogenesis in pulmonary stem/progenitor cells through Oct-4 hyperexpression.Oncotarget · 2016Article
- Combination of vascular endothelial growth factor-loaded microspheres and hyperbaric oxygen on random skin flap survival in rats.Experimental and therapeutic medicine · 2015Article
- Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.PloS one · 2015Article
- CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells.OncoTargets and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpression of the stem cell marker octamer 4 (Oct-4) in various neoplasms has been previously reported, but very little is currently known about the potential function of Oct-4 in this setting. The purpose of this study was to assess the prognostic value of Oct-4 expression after surgery in primary non-small cell lung cancer (NSCLC) and investigate its possible molecular mechanism.
methodsWe measured Oct-4 expression in 113 NSCLC tissue samples and three cell lines by immunohistochemical staining and RT-PCR. The association of Oct-4 expression with demographic characteristics, proliferative marker Ki67, microvessel density (MVD), and expression of vascular endothelial growth factor (VEGF) were assessed.
resultsOct-4 expression was detected in 90.3% of samples and was positively correlated with poor differentiation and adenocarcinoma histology, and Oct-4 mRNA was found in each cell lines detected. Overexpression of Oct-4 had a strong association with cells proliferation in all cases, MVD-negative, and VEGF-negative subsets. A Kaplan-Meier analysis showed that overexpression of Oct-4 was associated with shorter overall survival in all cases, adenocarcinoma, squamous cell carcinoma, MVD-negative, and VEGF-negative subsets. A multivariate analysis demonstrated that Oct-4 level in tumor tissue was an independent prognostic factor for overall survival in all cases, MVD-negative, and VEGF-negative subsets.
conclusionOur findings suggest that, even in the context of vulnerable MVD status and VEGF expression, overexpression of Oct-4 in tumor tissue represents a prognostic factor in primary NSCLC patients. Oct-4 may maintain NSCLC cells in a poorly differentiated state through a mechanism that depends on promoting cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.